Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM.

Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453.

PMID:
29750749
2.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629.

PMID:
29659371
3.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA.

Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628.

PMID:
29634490
4.

Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.

Bonhof CS, Mols F, Vos MC, Pijnenborg JMA, Boll D, Vreugdenhil G, Ezendam NPM, van de Poll-Franse LV.

Gynecol Oncol. 2018 Jun;149(3):455-463. doi: 10.1016/j.ygyno.2018.03.052. Epub 2018 Mar 28.

PMID:
29605500
5.

Shared decision-making in palliative care: desires and facts.

Vreugdenhil G.

Support Care Cancer. 2018 Jan;26(1):1-2. doi: 10.1007/s00520-017-3873-7. Epub 2017 Sep 15. No abstract available.

PMID:
28914362
6.

Cardiopulmonary resuscitation in cancer patients: still some problems to solve.

Osinski A, Vreugdenhil G.

Support Care Cancer. 2017 Aug;25(8):2367-2369. doi: 10.1007/s00520-017-3748-y. Epub 2017 May 26.

PMID:
28550442
7.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
8.

Electric vehicles. A small step towards improving air quality and mortality?

Vreugdenhil G.

Eur J Intern Med. 2017 Jan;37:e9-e10. doi: 10.1016/j.ejim.2016.10.015. Epub 2016 Nov 4. No abstract available.

PMID:
27823856
9.

Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.

Mols F, van de Poll-Franse LV, Vreugdenhil G, Beijers AJ, Kieffer JM, Aaronson NK, Husson O.

Eur J Cancer. 2016 Dec;69:28-38. doi: 10.1016/j.ejca.2016.09.020. Epub 2016 Nov 1.

PMID:
27814471
10.

Do-not-resuscitate orders in cancer patients: a review of literature.

Osinski A, Vreugdenhil G, de Koning J, van der Hoeven JG.

Support Care Cancer. 2017 Feb;25(2):677-685. doi: 10.1007/s00520-016-3459-9. Epub 2016 Oct 22. Review.

PMID:
27771786
11.

Sport and the city: midtown madness.

Vreugdenhil G, Mannaerts HF.

Lancet. 2016 Sep 24;388(10051):1277-8. doi: 10.1016/S0140-6736(16)31670-1. No abstract available.

PMID:
27673463
12.

Acetyl-L-carnitine undervalued in the treatment of chemotherapy-induced peripheral neuropathy?

van Dam DG, Beijers AJ, Vreugdenhil G.

Acta Oncol. 2016 Dec;55(12):1495-1497. Epub 2016 Sep 8. No abstract available.

PMID:
27606940
13.

The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.

Lobbezoo D, Truin W, Voogd A, Roumen R, Vreugdenhil G, Dercksen MW, van den Berkmortel F, Smilde T, van de Wouw A, van Kampen R, van Riel J, Peters N, Peer P, Tjan-Heijnen VC.

Oncotarget. 2016 May 17;7(20):29412-9. doi: 10.18632/oncotarget.8838.

14.

Abandoning diesel because of health perspectives: are there reasonable alternatives?

Vreugdenhil G, Mannaerts HF.

Ann Oncol. 2016 Jul;27(7):1360-1. doi: 10.1093/annonc/mdw166. Epub 2016 Apr 6. No abstract available.

PMID:
27052657
15.

Illness perceptions are associated with mortality among 1552 colorectal cancer survivors: a study from the population-based PROFILES registry.

Thong MS, Kaptein AA, Vissers PA, Vreugdenhil G, van de Poll-Franse LV.

J Cancer Surviv. 2016 Oct;10(5):898-905. doi: 10.1007/s11764-016-0536-5. Epub 2016 Mar 19.

16.

Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.

Razenberg LG, van Gestel YR, de Hingh IH, Loosveld OJ, Vreugdenhil G, Beerepoot LV, Creemers GJ, Lemmens VE.

BMC Cancer. 2016 Feb 16;16:110. doi: 10.1186/s12885-016-2158-8.

17.

Whole-Body Vibration as a Modality for the Rehabilitation of Peripheral Neuropathies: Implications for Cancer Survivors Suffering from Chemotherapy-Induced Peripheral Neuropathy.

Verhulst AL, Savelberg HH, Vreugdenhil G, Mischi M, Schep G.

Oncol Rev. 2015 Feb 10;9(1):263. doi: 10.4081/oncol.2015.263. eCollection 2015 Feb 10. Review.

18.

Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.

Beijers AJ, Vreugdenhil G, Oerlemans S, Eurelings M, Minnema MC, Eeltink CM, van de Poll-Franse LV, Mols F.

Support Care Cancer. 2016 Jun;24(6):2411-20. doi: 10.1007/s00520-015-3032-y. Epub 2015 Dec 3.

PMID:
26634561
19.

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.

Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA.

Qual Life Res. 2015 Dec;24(12):2895-906. doi: 10.1007/s11136-015-1039-y. Epub 2015 Jul 24.

20.

[Starting and stopping palliative tumour treatment: considerations in the context of quality of life and costs].

Vreugdenhil GA, van den Beuken-van Everdingen MH.

Ned Tijdschr Geneeskd. 2015;159:A8729. Dutch.

PMID:
26131748
21.

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.

Ayez N, van der Stok EP, de Wilt H, Radema SA, van Hillegersberg R, Roumen RM, Vreugdenhil G, Tanis PJ, Punt CJ, Dejong CH, Jansen RL, Verheul HM, de Jong KP, Hospers GA, Klaase JM, Legdeur MC, van Meerten E, Eskens FA, van der Meer N, van der Holt B, Verhoef C, Grünhagen DJ.

BMC Cancer. 2015 Mar 26;15:180. doi: 10.1186/s12885-015-1199-8.

22.

Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry.

Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O.

J Cancer Surviv. 2015 Sep;9(3):512-22. doi: 10.1007/s11764-015-0427-1. Epub 2015 Apr 16.

PMID:
25876556
23.

Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy.

Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G.

J Community Support Oncol. 2014 Nov;12(11):401-6. doi: 10.12788/jcso.0086.

PMID:
25856013
24.

Palliative care-oncology ward partnership: improving palliative care and integration of oncologic care.

Vreugdenhil G, Peerdeman A.

J Palliat Med. 2015 Mar;18(3):210. doi: 10.1089/jpm.2014.0400. Epub 2015 Feb 6. No abstract available.

PMID:
25658243
25.

The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry.

Vissers PA, Mols F, Thong MS, Pouwer F, Vreugdenhil G, van de Poll-Franse LV.

J Cancer Surviv. 2015 Sep;9(3):523-31. doi: 10.1007/s11764-015-0429-z. Epub 2015 Feb 3.

PMID:
25639748
26.

Comment on: 'Subgroup effects in a randomized trial of different types and doses of exercise during breast cancer chemotherapy'.

Beijers AJ, Verhulst AL, Mols F, Vreugdenhil G.

Br J Cancer. 2015 May 26;112(11):1835. doi: 10.1038/bjc.2014.614. Epub 2014 Dec 4. No abstract available.

27.

Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.

Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G.

Acta Oncol. 2015 Apr;54(4):463-9. doi: 10.3109/0284186X.2014.980912. Epub 2014 Nov 24.

PMID:
25417732
28.

[Chemotherapy-induced peripheral neuropathy; impact on quality of life].

Scheel A, Beijers AJ, Mols F, Faber CG, Vreugdenhil G.

Ned Tijdschr Geneeskd. 2014;158:A7455. Review. Dutch.

PMID:
25315326
29.

Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.

Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L.

Support Care Cancer. 2014 Aug;22(8):2261-9. doi: 10.1007/s00520-014-2255-7. Epub 2014 May 1. Review.

PMID:
24789421
30.

A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.

Beijers AJ, Mols F, Vreugdenhil G.

Support Care Cancer. 2014 Jul;22(7):1999-2007. doi: 10.1007/s00520-014-2242-z. Epub 2014 Apr 13. Review.

PMID:
24728618
31.

Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA.

Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8.

PMID:
24268350
32.

Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.

Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV.

J Clin Oncol. 2013 Jul 20;31(21):2699-707. doi: 10.1200/JCO.2013.49.1514. Epub 2013 Jun 17.

PMID:
23775951
33.

Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.

Kuper-Hommel MJ, van de Schans SA, Vreugdenhil G, van Krieken JH, Coebergh JW.

Leuk Lymphoma. 2013 Sep;54(9):1891-7. doi: 10.3109/10428194.2013.764421. Epub 2013 Feb 5.

PMID:
23302044
34.

Undertreatment of patients with localized extranodal compared with nodal diffuse large B-cell lymphoma.

Kuper-Hommel MJ, van de Schans SA, Vreugdenhil G, van Krieken JH, Coebergh JW.

Leuk Lymphoma. 2013 Aug;54(8):1698-705. doi: 10.3109/10428194.2012.753447. Epub 2012 Dec 31.

PMID:
23190406
35.

Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer.

Truin W, Voogd AC, Vreugdenhil G, van der Heiden-van der Loo M, Siesling S, Roumen RM.

Ann Oncol. 2012 Nov;23(11):2859-65. doi: 10.1093/annonc/mds180. Epub 2012 Jun 27.

PMID:
22745216
36.

Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.

Beijers AJ, Jongen JL, Vreugdenhil G.

Neth J Med. 2012 Jan;70(1):18-25. Review.

37.

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure.

Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G.

Support Care Cancer. 2012 Apr;20(4):877-81. doi: 10.1007/s00520-011-1336-0. Epub 2011 Dec 9.

38.

Rehabilitation using high-intensity physical training and long-term return-to-work in cancer survivors.

Thijs KM, de Boer AG, Vreugdenhil G, van de Wouw AJ, Houterman S, Schep G.

J Occup Rehabil. 2012 Jun;22(2):220-9. doi: 10.1007/s10926-011-9341-1.

PMID:
22081271
39.

Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease.

Kuper-Hommel MJ, Janssen-Heijnen ML, Vreugdenhil G, Krol AD, Kluin-Nelemans HC, Coebergh JW, van Krieken JH.

Leuk Lymphoma. 2012 Feb;53(2):242-6. doi: 10.3109/10428194.2011.607528. Epub 2011 Sep 19.

PMID:
21787261
40.

Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer.

Truin W, Voogd AC, Vreugdenhil G, van der Sangen MJ, van Beek MW, Roumen RM.

Breast. 2011 Dec;20(6):505-9. doi: 10.1016/j.breast.2011.05.005. Epub 2011 Jun 12.

PMID:
21665471
41.

[Sweet syndrome in underlying malignancy].

van Hirtum PV, Prins M, ten Oever J, Nijziel MR, Vreugdenhil G, Dercksen MW.

Ned Tijdschr Geneeskd. 2010;154:A2112. Dutch.

PMID:
21040604
42.

Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T; EORTC Leukemia Group.

Haematologica. 2010 Sep;95(9):1489-95. doi: 10.3324/haematol.2009.018580. Epub 2010 Apr 7.

43.

New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System.

van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW, Herings RM.

Eur J Cancer. 2010 Jan;46(2):395-404. doi: 10.1016/j.ejca.2009.09.010. Epub 2009 Oct 5.

PMID:
19811904
44.

Complete remission of MDS RAEB following immunosuppressive treatment in a patient with Sweet's syndrome.

Ten Oever J, Kuijper PH, Kuijpers AL, Dercksen MW, Vreugdenhil G.

Neth J Med. 2009 Sep;67(8):347-50.

45.

Impact of anthracycline dose on quality of life and rehabilitation in breast cancer treatment.

Hokken JW, van der Cruijsen-Raaijmakers M, Schep G, Vreugdenhil G.

Neth J Med. 2009 Jun;67(6):220-5.

46.

Resistance training in cancer survivors: a systematic review.

De Backer IC, Schep G, Backx FJ, Vreugdenhil G, Kuipers H.

Int J Sports Med. 2009 Oct;30(10):703-12. doi: 10.1055/s-0029-1225330. Epub 2009 Jul 7. Review.

PMID:
19585401
47.

Long-term cancer survivors experience work changes after diagnosis: results of a population-based study.

Mols F, Thong MS, Vreugdenhil G, van de Poll-Franse LV.

Psychooncology. 2009 Dec;18(12):1252-60. doi: 10.1002/pon.1522.

PMID:
19156675
48.

Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.

Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA, Vreugdenhil G, Herings RM, Coebergh JW, Voogd AC.

Eur J Cancer. 2008 Sep;44(13):1846-54. doi: 10.1016/j.ejca.2008.06.001. Epub 2008 Jul 17.

PMID:
18640030
49.

Long-term follow-up after cancer rehabilitation using high-intensity resistance training: persistent improvement of physical performance and quality of life.

De Backer IC, Vreugdenhil G, Nijziel MR, Kester AD, van Breda E, Schep G.

Br J Cancer. 2008 Jul 8;99(1):30-6. doi: 10.1038/sj.bjc.6604433. Epub 2008 Jun 24.

50.

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GM, Tesselaar ME, Slee PHTJ, Werter MJ, Mol L, Dalesio O, Punt CJ.

Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1.

PMID:
17630036

Supplemental Content

Loading ...
Support Center